A 2-year, Open-label Pilot Study Of Adjunctive Chromium In Patients With Treatment-resistant Rapid-cycling Bipolar Disorder
Notes for this study:
|Number of Subjects
In patients with bipolar disorder given between 600-800mcg chromium daily, it seemed that a minority of persons reported less depressive symptoms after three weeks (30% response as assessed by HAMD, 39% as assessed by MADRS) with no apparent benefit reported for manic symptoms nor any longer term benefits being reported due to dropouts.
No placebo control used in this study.